IHC4+Clinical (IHC4+C) combines the expression of oestrogen receptor, progesterone receptor, HER2 and Ki-67 with clinicopathological parameters (tumour size, grade, nodal status, age and endocrine treatment) to identify breast cancer patients at very low, low, intermediate or high risk of distant disease recurrence [23]. The gene discussed is PGR; the disease is breast cancer.